zonulin

Gut Healing

Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.

BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.